Scientific deep-dive

A Pill to Hold What the Injection Lost

Daily oral orforglipron maintained 79.3% of weight already lost against 37.6% on placebo at a year in people coming off semaglutide, and 74.7% against 49.2% after tirzepatide. The trial had no arm that stayed on the injection, which is the question people actually have.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
5 min read·1 citation

Plenty of people would like to lose the weight on an injection and then hold it with something simpler. A phase 3b trial tested that handover: participants who had lost weight on injectable semaglutide or tirzepatide moved to daily oral orforglipron or to placebo. In those coming off semaglutide, the pill maintained 79.3% of the reduction against 37.6% on placebo at 52 weeks. In those coming off tirzepatide, the figures were 74.7% against 49.2%.[1]

The result

In the semaglutide group the estimated treatment difference was 41.7 percentage points, with a confidence interval from 24.4 to 59.0. That is a wide interval, but comfortably clear of zero. In the tirzepatide group the difference was 25.5 points. All key secondary endpoints were met. The commonest adverse events were gastrointestinal and mostly mild to moderate.[1]

The placebo figure deserves its own look. People who switched to nothing still held 37.6% (after semaglutide) or 49.2% (after tirzepatide) of what they had lost, at a year. That is a third data point, after the real-world discontinuation data and SURMOUNT-4’s placebo arm, against the popular account that stopping means regaining everything.

The comparison that was not run

There was no arm that stayed on the injection.

The authors name this limitation themselves.[1] It matters more than any figure in the trial, because it is the question people have. Nobody wonders whether a pill beats stopping; obviously it does. What they want to know is whether switching costs them anything against staying on what was working.

We have one adjacent answer. In SURMOUNT-MAINTAIN, people who stepped down to a lower injectable dose held less than those who stayed at full dose, and needed rescue therapy three times as often (25% against 8%; see the maintenance trial). Less drug held much of the loss, but measurably less of it. Whether a switch to an oral agent behaves the same way is untested.

The trial is also only a year long, which the authors note. Maintenance is a question about years, and a 52-week answer to it is a beginning. Three other ways of using less drug (a lower labeled dose, a longer interval, a sub-labeled microdose) are set out in every other week. Switching to a different drug entirely is now a fourth.

Why an oral maintenance option matters commercially

The authors describe orforglipron as a potentially globally scalable option, and scalability is the point. Orforglipron is a small molecule rather than a peptide, so it can be manufactured at a scale injectable peptides cannot. Peptide manufacturing capacity is the constraint behind the shortages this register has tracked from the commercial end.

A world where the expensive, supply-constrained injectable does the losing and a manufacturable pill does the holding is a plausible answer to a real bottleneck. It is also a commercially convenient story. Watch whether the maintenance data ever gets a fair comparison against simply continuing.

Frequently Asked Questions

A phase 3b trial found daily oral orforglipron maintained 79.3% of the weight already lost against 37.6% on placebo at 52 weeks in people coming off semaglutide, and 74.7% against 49.2% in people coming off tirzepatide. It tested that handover directly, in a randomized trial.
Unknown, and this trial cannot say, because there was no arm that continued injectable therapy. The authors list that as a limitation. It is also the question most people want answered.
They held 37.6% (after semaglutide) or 49.2% (after tirzepatide) of the weight they had lost at one year. That is another data point against the idea that stopping means regaining everything, though it is clearly worse than continuing on something.
One year, which the authors also flag. Maintenance is a question about years, so a 52-week result is a starting point rather than a settled answer.
Because it is a small molecule rather than a peptide, so it can be manufactured at far greater scale. That bears directly on the supply constraints that have shaped this market.

References

  1. 1.Aronne LJ, Horn DB, le Roux CW, et al. Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial Nature Medicine. 2026. PMID: 42120723.

Every Other Week: Stretching the Interval

Patients moved to every-other-week dosing after a plateau held their weight and body composition over 36 weeks. It is a case series with no control group, and it is the third of three different ways to use less drug.

5 min read

Elecoglipron: A Second Oral GLP-1 Pill in Phase 2

Weight reductions from 2.6% to 10.5% at 26 weeks depending on dose, against 0.6% on placebo. 93% completed the study but only 75% completed the assigned treatment.

5 min read

Five Clicks Instead of a Quarter Milligram

One in five people on the label's titration schedule quit because of gut side effects. On a slower schedule it was one in fifty, at the same final dose, with the same results.

7 min read

Can You Lower the Dose and Keep the Weight Off?

Stepping down to 5 mg held 16.6% of body weight lost against 21.9% for staying at the full dose. But rescue therapy went from 8% to 25%, and to 67% on placebo.

6 min read

Not Taking It and Not Tolerating It

Real-world studies usually measure adherence and stopping separately, with every kind of stopping counted the same way. That merges someone whose body cannot tolerate the drug with someone not taking it reliably. A Scottish study separated them and found different predictors.

6 min read

The Cardiovascular Cost of Stopping

A review argues that weight and blood sugar fluctuation are themselves cardiovascular risk factors, and that these drugs do not stabilize arteries the way statins do. It also says few data exist on hard outcomes after stopping.

5 min read

Where to get GLP-1 online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

8.5

Gala

Moving between compounded and brand without changing seller

7.9

Luvo Health

Moving between compounded and brand without changing seller

7.2

Oak

A choice of compounded injections, oral semaglutide and brand-name GLP-1s from one cash-pay checkout

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →